Literature DB >> 17931152

Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations.

Christian Moser1, Mario Amacker, Andreas R Kammer, Silvia Rasi, Nicole Westerfeld, Rinaldo Zurbriggen.   

Abstract

Influenza virosomes are an efficient antigen carrier and adjuvant system that are approved for the use in human vaccines. Structurally, virosomes are spherical vesicles of approximately 150 nm in diameter, composed of a lipid membrane with integrated envelope proteins derived from influenza virus, predominantly hemagglutinin. The particle structure, together with the functions of hemagglutinin--receptor binding, pH-dependent fusion activity and immunostimulation--is responsible for the adjuvant effect of virosomes. In contrast to most other virus-like particles, virosomes are semisynthetic particles reconstituted in vitro from lipids and from virus-derived proteins. The production process has proven to be robust at industrial scale and fully compatible with Good Manufacturing Practice guidelines. At the same time, the formulation procedure is sufficiently flexible to allow modifications of the composition and structure for the intended use, including the positioning of the antigens of interest.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17931152     DOI: 10.1586/14760584.6.5.711

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  21 in total

1.  Novel antigen delivery systems.

Authors:  Maria Trovato; Piergiuseppe De Berardinis
Journal:  World J Virol       Date:  2015-08-12

Review 2.  Mucosal vaccines: recent progress in understanding the natural barriers.

Authors:  Olga Borges; Filipa Lebre; Dulce Bento; Gerrit Borchard; Hans E Junginger
Journal:  Pharm Res       Date:  2009-12-01       Impact factor: 4.200

3.  New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes.

Authors:  Mario Amacker; Charli Smardon; Laura Mason; Jack Sorrell; Kirk Jeffery; Michael Adler; Farien Bhoelan; Olga Belova; Mark Spengler; Beena Punnamoottil; Markus Schwaller; Olivia Bonduelle; Behazine Combadière; Toon Stegmann; Andrew Naylor; Richard Johnson; Desmond Wong; Sylvain Fleury
Journal:  NPJ Vaccines       Date:  2020-05-18       Impact factor: 7.344

4.  Membrane Env Liposomes Facilitate Immunization with Multivalent Full-Length HIV Spikes.

Authors:  Daniel P Leaman; Armando Stano; Yajing Chen; Lei Zhang; Michael B Zwick
Journal:  J Virol       Date:  2021-06-10       Impact factor: 5.103

5.  Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes.

Authors:  Geert Leroux-Roels; Cathy Maes; Frédéric Clement; Frank van Engelenburg; Marieke van den Dobbelsteen; Michael Adler; Mario Amacker; Lucia Lopalco; Morgane Bomsel; Anick Chalifour; Sylvain Fleury
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

Review 6.  Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines?

Authors:  Sharan Bobbala; Sarah Hook
Journal:  Pharm Res       Date:  2016-07-05       Impact factor: 4.580

7.  Immunogenicity of a recombinant influenza virus bearing both the CD4+ and CD8+ T cell epitopes of ovalbumin.

Authors:  Bruno Garulli; Giuseppina Di Mario; Ester Sciaraffia; Yoshihiro Kawaoka; Maria R Castrucci
Journal:  J Biomed Biotechnol       Date:  2011-10-05

Review 8.  Recent advances of vaccine adjuvants for infectious diseases.

Authors:  Sujin Lee; Minh Trang Nguyen
Journal:  Immune Netw       Date:  2015-04-23       Impact factor: 6.303

9.  Recent trends in vaccine delivery systems: A review.

Authors:  Ch Saroja; Pk Lakshmi; Shyamala Bhaskaran
Journal:  Int J Pharm Investig       Date:  2011-04

10.  Induction of antibodies and T cell responses by a recombinant influenza virus carrying an HIV-1 TatΔ51-59 protein in mice.

Authors:  B Garulli; G Di Mario; M G Stillitano; D Compagnoni; F Titti; A Cafaro; B Ensoli; Y Kawaoka; M R Castrucci
Journal:  Biomed Res Int       Date:  2014-05-14       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.